Amedisys (AMED) Tops Q3 EPS by 96c

Amedisys (NASDAQ: AMED) reported Q3 EPS of $2.24, $0.96 better than the analyst estimate of $1.28. Revenue for the quarter came in at $544.1 million versus the consensus estimate of $533.18 million.

Paul B. Kusserow, President and Chief Executive Officer stated, “I am very proud of our third quarter results which have bested both our internal and external expectations and have allowed us to increase our full year 2020 guidance ranges. Home health and hospice have shown strong recoveries and returned to growth this quarter which is no small feat given the continued impact of COIVD-19. We are well underway with our integration of Aseracare, have paid down a large portion of our already low debt and continue to drive prodigious amounts of cash flow. Most importantly, we have done all of this while delivering the highest quality care and continuing our relentless focus on clinical quality. The importance of caring for people in their homes, wherever they call home, has never been more evident, and as such, we are well positioned for continued success. A special thank you to all of our clinician staff for continuing to do what you do best. It is because of your compassion, bravery and tireless efforts that we are able to deliver another great quarter.”

GUIDANCE:

Amedisys sees FY2020 EPS of $6.02-$6.08, versus the consensus of $4.98. Amedisys sees FY2020 revenue of $2.067-2.072 million, versus the consensus of $2.06 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Schlumberger (SLB) earnings in-line, revenue beats expectations
• Oilfield firm SLB's profit rises on international drilling demand
• Parke Bancorp (PKBK) Reports Q1 EPS of $0.51